Respond to prefers-color-scheme dark in app web views

Follow section front redirects in Spectrum

Enable NLP source in PCS for load testing

Switch off the News Alerts Survey Widget when we have enough responses

Poll to determine if new LUF updates are available

Allows the winning A/B test variant to be turned on without Spectrum deployment

Show infinite scrolling sections in Assembler MultiView

Show option for NLP article summaries in Action Bar

A general feature flag for Recipe Features that aren't yet released

Feature flag for media team features that aren't yet released

Use new Orca video player for preroll plugin in Spectrum

Show the snow tracker (instead of the heat tracker) on Spectrum

Election 2024 latest news: Biden holding events in battleground state of North Carolina

That time football legend, rig-driving eligible bachelor Biden was arrested

Campuses are grappling with the Gaza war. So are our columnists.

Stephen A. Smith would like even more of your attention

Wait, what is Stephen A. Smith talking about? Find out with our quiz.

Local sports networks go dark mid-game amid dispute with Comcast 

The beginner’s illustrated guide to watching an F1 race

Police arrest pro-Palestinian protesters at Columbia

What’s the best bus to New York? We tested 5 for comfort and value.

Adaptive equipment is making national parks more inclusive

Southwest passengers now get a $75 voucher for big flight disruptions

Cat climbed into Amazon return box, found alive 630 miles away

I learned to heal my sadness by cradling dying chickens 

Brave Little Hunter is free: Baby orca escapes lagoon for open seas

Trevor Williams’s escape act helps Nationals blank Rangers 

How the Nationals helped Mitchell Parker develop into a big leaguer

The 33 best things to do in D.C. this weekend and next week

Carolyn Hax: Will request for a postnup offend much younger wife?

Ask Sahaj: Responding to microaggressions is taking a toll on me. Can I stop?

Miss Manners: Offering my bedroom to guests

Young Georgians want to be part of Europe. Their government is in the way.

Taxes are inevitable. Paying to prepare them doesn’t have to be.

A murder plot that cannot be ignored: India must come clean at last

Middle East conflict live updates: Hamas says it views talks favorably; Blinken urges group to accept deal

Money goes elsewhere, aid workers flee, Haitians endure on their own

Why the Solomon Islands election matters to China and the U.S.

Russian state media ramping up English, Spanish presence on TikTok, study finds

Microsoft is changing how you log in to your accounts

Apple is behind in AI and killed its self-driving car project. What’s next?

Trump and allies say Biden pays rent for ‘illegals’ in Michigan. Not true.

Eighty percent of Ukraine-Israel bill will be spent in U.S. or by U.S. military

US President Joe Biden Departure

Biotech and pharmaceutical stocks <a href="https://www.washingtonpost.com/news/wonk/wp/2016/11/14/trump-just-dropped-a-big-hint-to-the-pharmaceutical-industry/?utm_term=.95c9ca9a2923" target="_blank">rose after the election</a>, reflecting investor optimism that a Trump presidency would mean less focus on drug prices. Not so fast, president-elect Trump said in his interview for Time '<a href="http://time.com/time-person-of-the-year-2016-donald-trump/" target="_blank">Person of the Year</a>.'

“I’m going to bring down drug prices,” Trump told Time in an interview in his dining room after the election. “I don’t like what has happened with drug prices.”

No additional detail about what Trump would do to lower drug prices was available, and his transition team did not immediately respond to requests for more information.

But Adam Fein, president of Pembroke Consulting, a firm focused on pharmaceutical economics, said that what Trump may be doing is sending a signal to the industry.

“Historically, a lot of manufacturers have increased the prices of their products at the beginning of the year,” Fein said. “I think that president-elect Trump is trying to send a message to sort of encourage manufacturers to not take their usual price increases. . . . He may be trying to use his bully pulpit to signal, 'you should change the system' -- without necessarily saying how he’s going to change the system, or what should be done.”

Pharmaceutical and biotech stocks were down in mid-day trading. The S&P Pharmaceuticals Select Industry Index was down 3.4 percent and the NASDAQ Biotechnology Index was down 4.2 percent at 11:30 a.m.

Some pharmaceutical executives, believing that the drug price debate isn't likely to recede, have pressed the industry to get in front of the issue to avoid government intervention. Brent Saunders, chief executive of Allergan, wrote a blog post in September vowing to limit drug prices to single-digit percentage price hikes, once a year. Danish diabetes giant Novo Nordisk <a href="http://press.novonordisk-us.com/leadership-perspectives?item=1" target="_blank">followed suit</a> with a similar pledge last week.

“We hear from more and more people living with diabetes about the challenges they face affording healthcare, including the medicines we make,” wrote Jakob Riis, Novo Nordisk's U.S. president. “This has become a responsibility that needs to be shared among all those involved in healthcare and we’re going to do our part.”


<i>
    [One pharmaceutical company’s unusual solution to public fury over price hikes]
  </i>


President-elect Trump's unpredictability has already made companies in multiple industries <a href="https://www.washingtonpost.com/business/economy/trumps-unpredictable-style-unnerves-corporate-america/2016/12/06/6e3f3976-bbea-11e6-94ac-3d324840106c_story.html?hpid=hp_rhp-top-table-main_trumpstockprint905pm%3Ahomepage%2Fstory&amp;utm_term=.d65eab0a2409" target="_blank">nervous</a>. Drug companies may refrain from big price hikes simply to stay out of his crosshairs, since the pharmaceutical industry -- already under intense scrutiny because of price hikes -- could be an easy target.

Fein also noted that Trump may have industry tailwinds -- drug companies have increasingly begun to talk publicly about pricing and the warped incentives that exist in the current system. List prices are generally recognized as a fiction. Traditionally, list prices do not reflect what anyone in the system pays for a drug -- or what drug companies receive -- due to a complex system of payments to middlemen and secret rebates and discounts. But as health plans have shifted toward high-deductible plans or coinsurance, patients are being affected by the list prices of drugs, and drug companies have increasingly begun to acknowledge and focus on the problem.

It's hard to know whether the Trump administration would support other policy levers to rein in drug prices. But a signal may be in his choice of Tom Price to head the Department of Health and Human Services.

In 2007, Price said that allowing Medicare to negotiate on drug prices, for example, was a “<a href="http://www.nytimes.com/2007/01/12/washington/12cnd-drug.html" target="_blank">solution in search of a problem</a>,” according to the New York Times.

<a href="https://www.washingtonpost.com/news/wonk/wp/2016/10/31/why-insulin-prices-have-kept-rising-for-95-years/?utm_term=.25fbdf85a48f" target="_blank">Why treating diabetes keeps getting more expensive</a>

<a href="https://www.washingtonpost.com/news/wonk/wp/2016/11/03/these-researchers-think-they-have-a-solution-to-the-global-crisis-in-drug-prices/?utm_term=.96be5cd56891" target="_blank">These researchers think they have a solution to the global crisis in drug prices</a>

<a href="https://www.washingtonpost.com/news/wonk/wp/2016/02/25/why-america-pays-so-much-more-for-drugs/?utm_term=.bda454a56bce" target="_blank">Why America pays so much more for drugs</a>

<a href="https://www.washingtonpost.com/news/wonk/wp/2016/11/07/the-bizarre-reason-two-competing-drug-prices-rose-in-tandem/?utm_term=.dc9b8a237985" target="_blank">The bizarre reason two competing drug prices rose in tandem</a>

Finalist for the 2013 Pulitzer Prize in national reporting, as part of a team

Amherst College, BA in Physics and English

MIT, MS in Science Writing

Carolyn Johnson is a science reporter. She previously covered the business of health and the affordability of health care to consumers. 